ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / EHC / financials
ENSG (72) UHS (63) PACS (74) THC (74) ⌘ Pro Terminal →

Encompass Health Corporation (EHC) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$135.90 +3.35% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $137.05

Encompass Health Corporation (EHC) earns a Roarable Rating of B+ (Buy) with 77/100 RQD Confidence. High-quality cash engine (steady margins, 14% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 77/100 (B+) historically ranked in the Top 10% of excess returns over the next 90 days (+7.8% avg 90D alpha vs SPY • 70.3% hit rate) →
ROARABLE B+ • BUY Cap $12.97B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on EHC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is EHC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Encompass Health Corporation (NYSE: EHC) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 77/100 at a spot price of $135.90 (+3.35% 1D, market cap $12.97B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, EHC ranks #27 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does EHC compare to ENSG and UHS in the Health Care sector?
▼

Within the Health Care sector (Hospital/Nursing Management), EHC carries a Roarable B+ (77/100 RQD), trailing P/E of 22.9x, gross margin of —, and ROIC of 13.8%. By comparison, ENSG (The Ensign Group Inc.) holds a B grade (72/100 RQD, P/E 31.6x, ROIC 18.0%, cap $10.87B) and UHS (Universal Health Services Inc.) posts a C grade (63/100 RQD, P/E 7.0x, ROIC 14.1%, cap $10.41B). Among the 5-stock peer group, UHS leads on earnings multiple (7.0x) while THC leads on capital efficiency (27.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for EHC?
▼

Per EHC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000785161), Encompass Health Corporation generated $5.94B in revenue (+10.5% YoY), $566.2M in net income, and $0 in free cash flow against $7.09B in total assets and $1.72B in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $137.04 (+0.84%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 15/20 (B) • 6.4% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 77/100 (B+) historically ranked in the Top 10% of excess returns over the next 90 days (+7.8% avg 90D alpha vs SPY • 70.3% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B+
025507510077
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B+ · Rk B
Cash (15)Whales (18)SEC (16)Macro (13)CEO (15)
Each axis scored 0–20
12M PRICE TARGET CONE+8.6% Base Target
$174 Bull$148 Base$111 Bear
📬 FREE EHC RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EHC)Realized 20D OHLCV Swing Band: ±7.1%
Deterministic 5-Pillar Attribution (77/100 Composite)
🔍 WHY EHC SCORES 77/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+18/20 pts (23% of score)

20D Institutional Volume Accumulation (±7.1% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (21% of score)

Altman Z-Score 3.47 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▼ #1 Drag / Risk Factor: Macro Regime Fit13/20 pts (-7 pt drag)

Macro rate sensitivity & RSI-14 (60.3) create a -7 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
69
Grade B-$124.33-2.1% Next Q
Q2 (-2Q)
72
Grade B$121.67-0.1% Next Q
Q3 (-1Q)
74
Grade B+$121.53+11.8% Next Q
Current
77
Grade B+$135.90+7.8% Hist 90D α
Trajectory: B- (69) → B+ (77)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the EHC Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 77/100 (B+) score, EHC faces multiple-compression risk if 22.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($123.28) or 200D SMA ($110.34) invalidates the momentum regime and cuts Target Base ($147.52) toward Bear Floor ($111.44).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EHC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “EHC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 77%NO 23%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How EHC Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$378.8M (6.4% FCF Margin)
Revenue$5.94BGross Profit $3.09B (52%)Cost of Sales $2.85BOp Profit $668.1M (11.3%)OpEx (R&D/SG&A) $2.42BNet Profit$566.2M (9.5%)Tax/Other $101.9M

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow
FY23
Rev $4.80B
FY24
Rev $5.37B
FY25
Rev $5.94B
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$5.94B52%11.3%$566.2M$537.9M12.9%
FY 2024$5.37B52%10%$455.7M$432.9M11.7%
FY 2023$4.80B52%8.7%$352.0M$334.4M7.6%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EHC)

  • ✓Walkthrough of EHC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
EHC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +27.44%⚡ TESTING RESISTANCE
2026-11-02O $122.1H $135.9L $122.1C $135.9VOL 2.20M
RES: $137.6SUP: $121.7SMA50: $123.3SMA200: $110.3
$140.1$128.3$116.4$104.6$92.75RES $137.6SUP $121.7$135.92026-05-042026-06-172026-08-042026-09-182026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EHC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EHC Butterfly Map → + Track EHC →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
16.7%/yr Implied 5Y Growth

vs. +10.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on EHC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EHC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for EHC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EHC)

Health Care Rank #27 of 1016 ⚔️ ENSG vs EHC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EHC vs. ENSG, UHS, PACS, THC)

Industry: Hospital/Nursing Management (14 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Encompass Health Corporation (EHC) ranks #27 by composite RQD confidence (77/100, grade B+) and #86 by equity capitalization ($12.97B). Within this direct 5-issuer industry benchmark cohort, UHS leads on earnings valuation at 7.0x trailing P/E, while THC leads on capital efficiency and profitability with 27.6% ROIC and — gross margin. EHC currently leads its immediate peer cohort in composite quantitative strength at 77/100 (B+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
EHC ACTIVE
Encompass Health Corporation
B+ 77/100 22.9x — 13.8% +3.35% $12.97B Benchmark Subject
ENSG
The Ensign Group Inc.
B 72/100 31.6x 20.1% 18.0% -2.58% $10.87B /ensg-vs-ehc →
UHS
Universal Health Services Inc.
C 63/100 7.0x — 14.1% -0.32% $10.41B /uhs-vs-ehc →
PACS
PACS Group Inc.
B 74/100 41.1x — 24.6% -3.76% $7.87B /pacs-vs-ehc →
THC
Tenet Healthcare Corporation
B 74/100 9.2x — 27.6% +0.99% $21.79B /thc-vs-ehc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000785161

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Encompass Health Corporation (EHC) reported GAAP revenue of $5.94B (+10.5% vs. FY2024 revenue of $5.37B , and +23.6% cumulative change since FY2023) , GAAP net income of $566.2M, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, EHC closed FY2025 with $7.09B in total assets against $1.72B in total debt (Altman Z-Score: 3.47, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $5.94B $566.2M — — $7.09B $1.72B
FY2024 (FY) 2024-12-31 $5.37B $455.7M — — $6.53B $1.66B
FY2023 (FY) 2023-12-31 $4.80B $352.0M — — $7.13B $1.67B

3. EHC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EHC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Encompass Health Corporation (NYSE: EHC) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 77/100 at a spot price of $135.90 (+3.35% 1D, market cap $12.97B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, EHC ranks #27 in composite RQD confidence.

How does EHC compare to ENSG and UHS in the Health Care sector?

Within the Health Care sector (Hospital/Nursing Management), EHC carries a Roarable B+ (77/100 RQD), trailing P/E of 22.9x, gross margin of —, and ROIC of 13.8%. By comparison, ENSG (The Ensign Group Inc.) holds a B grade (72/100 RQD, P/E 31.6x, ROIC 18.0%, cap $10.87B) and UHS (Universal Health Services Inc.) posts a C grade (63/100 RQD, P/E 7.0x, ROIC 14.1%, cap $10.41B). Among the 5-stock peer group, UHS leads on earnings multiple (7.0x) while THC leads on capital efficiency (27.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for EHC?

Per EHC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000785161), Encompass Health Corporation generated $5.94B in revenue (+10.5% YoY), $566.2M in net income, and $0 in free cash flow against $7.09B in total assets and $1.72B in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is EHC trading relative to its 50-day, 200-day, and 52-week technical levels?

EHC last traded at $135.90 (+3.35% on volume of 1,797,779 shares), positioning the stock +10.24% above its 50-day simple moving average ($123.28) and +23.16% above its 200-day simple moving average ($110.34). Across its 52-week range of $92.77 to $137.27, EHC sits at the 96.9% percentile with a 14-day RSI of 60.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.1% ($126.25 to $145.55).

EHC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Encompass Health Corporation (EHC)?

In FY 2025 (10-K), EHC converted $5.9B of revenue into a 52% gross margin, 11.3% operating margin, and $378.8M in free cash flow (6.4% FCF margin).

Direct Sub-Reports: EHC RQD Cockpit EHC 12M Forecast EHC Earnings & Move EHC Dividends & DRIP EHC Insiders & 13F EHC Whale Options EHC Profit Sankey EHC News & Why
ROARABLE RATING BRIEF • RQD 77/100 (B+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

EHC — Encompass Health Corporation: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:15:18Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating is 77 out of 100, graded B+ and labeled "Roarable Buy — Very Good Cash & Smart-Money Inflow" (per the Roarable RQD rating). The five pillars are:

  • Fundamental Cash Engine: 15 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of 13.8% and an FCF yield of 2.92%. For a prospective investor, the cash engine is respectable rather than exceptional: returns on invested capital are solid, but the free cash flow yield of 2.92% implies the market is paying a meaningful premium for each dollar of free cash flow generated.
  • Whale 13F Flow: 18 / 20. Per the Roarable RQD rating, this is the strongest pillar, described as institutional accumulation and options positioning. This signals that large institutional holders have been adding exposure, which can support price momentum, though the source data does not itemize the holdings behind this score.
  • Insider Conviction: 15 / 20. Per the Roarable RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. The score indicates moderately positive insider and disclosed-trade activity, though the underlying transactions are not itemized in the source data.
  • Macro Regime Fit: 13 / 20. Per the Roarable RQD rating, beta is 0.9 and sector sensitivity is reflected here. A beta below 1.0 suggests the stock has historically moved less than the broader market, which can cushion drawdowns but also limits participation in strong market rallies.
  • Forensic Balance Sheet: 16 / 20. Per the Roarable RQD rating, this pillar reflects Altman Z 3.47, Piotroski F 9/9, and Debt/Equity 0.66. These readings point to a financially sound balance sheet, a relevant consideration for a prospective investor weighing downside risk.

Investor implications: the composite score points to a generally favorable profile, with institutional flow and balance sheet strength as the main supports. The tradeoffs are a relatively elevated trailing P/E of 22.9 (per Market Data), a 2.92% FCF yield, and a macro-sensitivity score that is the weakest of the five pillars. Upside drivers in the data are institutional accumulation and recent earnings momentum; valuation compression or a shift in sector sentiment would be the principal risks to that thesis. This analysis is educational and is not personalized financial advice.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
$131.49$12.97B22.921.315.85.740.55%0.9$92.77 - $137.2713.8%

Business

Encompass Health Corporation (EHC) is a NYSE-listed issuer in the Health Care sector, operating in the Hospital/Nursing Management industry (per the Profile). Per the Profile, the company carries a market capitalization of $13.0B. The source data does not describe its specific services, customer base, or revenue model beyond the sector and industry classification. Not available in source data for the remaining business details.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025 (filed 2025-12-31)$5935.2M$668.1M$566.2MN/AN/A$72.2M$1716.3M
FY 2024 (filed 2024-12-31)$5373.2M$537.7M$455.7MN/AN/A$85.4M$1658.5M
FY 2023 (filed 2023-12-31)$4801.2M$415.4M$352.0MN/AN/AN/A$1669.5M

Per the SEC financials, revenue rose from $4801.2M in FY 2023 to $5935.2M in FY 2025, and net income rose from $352.0M to $566.2M over the same span. Per Market Data, the operating margin is 11.6% and the net margin is 9.5%, with ROIC of 13.8%. Per the Roarable RQD rating, the Altman Z-Score is 3.47 and the Piotroski F-Score is 9/9, with Debt/Equity at 0.66. The reported debt has trended from $1669.5M to $1716.3M across the three periods, while cash declined from $85.4M to $72.2M between FY 2024 and FY 2025.

Recent Catalysts & News Wire Analysis

  • Earnings result: A headline reports Q3 adjusted EPS of $1.52 per share versus a FactSet estimate of $1.36 (per the News Wire, marketscreener.com). This is the most concrete fundamental catalyst in the feed.
  • Earnings materials: A Q3 2026 earnings call presentation dated 2026-11-01 is referenced (per the News Wire, Seeking Alpha).
  • Price action: Multiple headlines note the stock rising and reaching a 52-week high (per the News Wire). Per Market Data, the price changed 7.7% and volume was 2,197,689.
  • Risk watch: The news feed is uniformly labeled YELLOW with "MARKET WIRE" impact, indicating no high-severity red flags are flagged in the source. The feed does not contain specific litigation, regulatory, or guidance-risk items.
  • Proprietary signals: None. Per the Butterfly Supply-Chain Graph, the supply chain is NONE and proprietary signals are empty.

Open Questions

  • What is the composition of revenue and operating income by business segment, and how much depends on payer mix or reimbursement policy?
  • What are the reported EPS and free cash flow figures for the FY periods, since the financials list them as N/A?
  • Why did cash decline between FY 2024 and FY 2025, and what is the debt maturity and refinancing profile behind the $1716.3M balance?
  • What are the actual Q3 guidance revisions and the drivers behind the reported adjusted EPS beat?
  • Who are the specific institutional and insider holders behind the 13F and Form 4 signals that drive the RQD pillar scores?

EHC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Encompass Health Corporation (EHC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to EHC Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

EHC Bull vs. Bear Conversation Board — What's Your Call at $135.90?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EHC 🐻 33% BEARISH CONVICTION
1. Pick Your Side on EHC:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $155.16 (+18.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is EHC (B+ • RQD 77/100) a Buy at $131.49?

Welcome to the EHC (Encompass Health Corporation) Roar Pit. Current RQD Composite is 77/100 (Roarable Buy — Very Good Cash & Smart-Money Inflow) in Hospital/Nursing Management. Bulls point to capital efficiency (13.8% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $102.56 (-22.0%)
Spot @ $131.49

Pump the brakes on EHC — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on EHC, but look at what you are paying: 22.9x trailing P/E with tightening sector spreads. Unless Encompass Health Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $151.21 (+15.0%)
Spot @ $131.49

EHC cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on EHC, the market is fixating on short-term headline noise in Hospital/Nursing Management and ignoring the balance sheet and cash flow trajectory. At $131.49 (52-wk range $92.77 - $137.27), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%